Search This Blog

Tuesday, August 25, 2020

Metacrine’s lead drug Fast Track’d for NASH

The FDA designates Metacrine’s (MTCR) lead program, MET409 for Fast Track review for the treatment of non-alcoholic steatohepatitis (NASH).

MET409 targets farnesoid X receptor (FXR) a protein which plays a key role in modulating said diseases.

Recently, the company filed for $100M IPO.


Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)